LMP2A/MYC transgenic mice are born with enlarged spleens, and lymphadenopathy can be readily detected by 5 to 6 weeks of age, whereas MYC transgenic mice do not show splenomegaly or lymphadenopathy until they develop tumors. This evidence concerns the gene MYC and Splenomegaly.